Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.

NCT07465718 is registered in ClinicalTrials.gov with Orphalan as lead sponsor.

NCT NCT07465718
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07465718 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.
Lead sponsor
Orphalan
Phase
Phase 3
Overall status
Recruiting
Start date
September 3, 2026
Completion date
February 29, 2028
Enrollment
38 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

wilson's disease